Treatment for endometrial hyperplasia depends almost entirely on one factor: whether the overgrown uterine lining contains abnormal-looking cells, called atypia. Hyperplasia without atypia is treated with hormonal medication and has a low risk of becoming cancer (under 3% per year). Hyperplasia with atypia carries an 8% annual risk of progressing to endometrial cancer, and the standard treatment is surgical removal of the uterus.
Why the Type of Hyperplasia Determines Treatment
Since 2014, the WHO has simplified endometrial hyperplasia into just two categories: hyperplasia without atypia (sometimes called benign hyperplasia) and atypical hyperplasia, also known as endometrial intraepithelial neoplasia or EIN. The older system used four categories, but the simplified version reflects what actually matters for treatment decisions.
Hyperplasia without atypia responds well to progesterone-based therapy, and fewer than 5% of cases ever develop into cancer. Atypical hyperplasia is a precancerous condition. A meta-analysis in PLOS One found that roughly one-third of women diagnosed with atypical hyperplasia already have an undetected endometrial cancer at the time of diagnosis. That high concurrent cancer rate is the main reason surgery is so strongly recommended.
Hormonal Treatment for Hyperplasia Without Atypia
Progesterone-based medications are the first-line treatment for hyperplasia without atypia. Progesterone counteracts the excess estrogen that caused the lining to overgrow, thinning it back to normal. There are two main delivery methods, and they differ significantly in effectiveness.
A progesterone-releasing intrauterine device (the hormonal IUD) achieves a 93% regression rate, meaning the hyperplasia fully resolves. Oral progesterone pills achieve about 66% regression. That gap is large enough that many guidelines now favor the IUD as the preferred option. The IUD delivers progesterone directly to the uterine lining with fewer side effects than pills, and it works continuously without requiring you to remember a daily dose. In studies, the median time to regression was around 10 months for both methods.
When oral progesterone pills fail as a first treatment, switching to the IUD still works well. In one study, 93% of women who didn’t respond to oral pills achieved regression after switching to the IUD. Women who stayed on oral pills after initial failure had only a 55% regression rate.
Monitoring During Treatment
Treatment isn’t a matter of starting medication and waiting. You’ll need repeat endometrial biopsies to confirm the hyperplasia is actually resolving. Guidelines from different countries vary slightly on the exact schedule, but the general framework looks like this:
- For hyperplasia without atypia on oral progesterone: A first biopsy around 3 months into treatment, then another shortly after completing the course. With the hormonal IUD, biopsies every 3 to 6 months while the device stays in place.
- For atypical hyperplasia managed conservatively: Biopsies every 3 to 6 months, continued until at least two consecutive results come back normal. Long-term monitoring every 6 to 12 months is recommended until a hysterectomy is eventually performed.
The Royal College of Obstetricians and Gynaecologists recommends at least two consecutive negative biopsies, taken 6 months apart, before considering a patient cleared. For anyone at high risk of recurrence, annual surveillance should continue long-term.
Hysterectomy for Atypical Hyperplasia
Total hysterectomy, typically with removal of both ovaries and fallopian tubes, is the standard treatment for atypical hyperplasia. Both ACOG and European guidelines recommend it as first-line therapy. Because of the high rate of hidden concurrent cancer, surgeons often examine the removed uterus during the operation itself to check for malignancy, which could change what additional steps are needed.
One important detail: a partial (supracervical) hysterectomy, which leaves the cervix in place, is not appropriate for atypical hyperplasia. The abnormal tissue can extend into the lower part of the uterus or upper cervix, and leaving the cervix behind risks leaving disease behind.
Fertility-Sparing Treatment for Atypical Hyperplasia
For younger women who want to become pregnant, conservative management with progesterone therapy is an option, but it comes with serious caveats. Before starting this path, imaging and sampling should be thorough enough to rule out an existing cancer that might be undertreated with hormones alone.
Women on this path take higher-dose progesterone (oral, via IUD, or both) and undergo biopsies every 3 to 6 months. The goal is to achieve regression, conceive, and then proceed with hysterectomy once childbearing is complete. If the hyperplasia doesn’t respond to hormonal therapy, or if it comes back after initial regression, hysterectomy is recommended regardless of fertility plans. This is not a permanent alternative to surgery. It’s a way to buy time for pregnancy before definitive treatment.
Weight Loss and Metabolic Treatment
Excess body fat drives endometrial hyperplasia by raising circulating estrogen levels. Fat tissue converts other hormones into estrogen, and obesity also promotes insulin resistance, which further stimulates estrogen production. Addressing these metabolic factors meaningfully improves treatment outcomes.
A study of 202 patients found that women who lost more than 3% of their body weight during progestin treatment had a disease reversal rate of 91%, compared to 78% for those who didn’t lose weight. That’s a meaningful boost on top of the hormonal therapy alone. The weight loss threshold was modest: just 3% of body weight, which for a 200-pound person is 6 pounds.
For women with insulin resistance, adding metformin to progestin therapy also improved outcomes substantially. The metformin group achieved a 93% reversal rate, compared to 52% without metformin. Metformin works by lowering circulating insulin and glucose levels, which in turn reduces the hormonal signals that drive the uterine lining to overgrow. At follow-up beyond 12 months, metformin users also had lower recurrence rates (13% versus 29%). Both weight loss and metformin use were independently protective, meaning each one helps on its own, and the combination is stronger than either alone.
What Happens if Treatment Doesn’t Work
For hyperplasia without atypia that doesn’t regress after a course of oral progesterone, the next step is usually switching to the hormonal IUD, which has strong evidence of rescuing initial treatment failures. If the hyperplasia persists despite the IUD, or if it progresses to atypical hyperplasia on a follow-up biopsy, hysterectomy becomes the recommended path.
For atypical hyperplasia managed conservatively, failure to achieve regression after an adequate trial of progesterone therapy, or recurrence after initial success, is a clear signal to proceed with hysterectomy. The ongoing cancer risk is too high to continue watching indefinitely. Recurrence is common enough that even women who achieve full regression need continued surveillance for years afterward.